Dr. Edward Romond, a cancer specialist and researcher at UK HealthCare's Markey Cancer Center, was instrumental in researching and analyzing the results of two massive clinical trials of early-stage breast cancer patients who received Herceptin in combination with chemotherapy. The results indicated a 52 percent decrease in the risk for breast cancer recurrence compared with patients who received the same chemotherapy without Herceptin. "In terms of a single leap forward, this is probably the most dramatic we've had in a long time," Romond said.
The study revealed the use of Herceptin in early-stage HER-2 positive breast cancer was effective. Herceptin was previously only used in late-stage breast cancer or cancer that had spread to other sites. The effectiveness of this new treatment therapy offers hope to the 25 percent of breast cancer patients who have HER-2 positive breast cancer, which is an extremely aggressive and fast-spreading cancer. This study has changed the outcome from one of the most worrisome kinds of cancer to one that has a much better prognosis, Romond said.
The NCI-sponsored national clinical trial featured more than 500 testing sites throughout the United States and Canada and included 3,351 women. Romond has since become the national spokesperson for this new use of Herceptin in treating early-stage HER-2 positive breast cancer.
Amanda W. Nelson | EurekAlert!
Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
23.02.2017 | Physics and Astronomy
23.02.2017 | Earth Sciences
23.02.2017 | Life Sciences